annb0t
Top 20
ResMed (NYSE:RMD) Full Year 2024 Results
Key Financial Results
Revenue: US$4.69b (up 11% from FY 2023). Net income: US$1.02b (up 14% from FY 2023). Profit margin: 22% (in line with FY 2023). EPS: US$6.94 (up from US$6.12 in FY 2023). revenue-and-expenses-breakdown
All figures shown in the chart above are for the trailing 12 month (TTM) period
ResMed Meets Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.
The primar...
>>> Read more: ResMed Full Year 2024 Earnings: In Line With Expectations
Key Financial Results
Revenue: US$4.69b (up 11% from FY 2023). Net income: US$1.02b (up 14% from FY 2023). Profit margin: 22% (in line with FY 2023). EPS: US$6.94 (up from US$6.12 in FY 2023). revenue-and-expenses-breakdown
All figures shown in the chart above are for the trailing 12 month (TTM) period
ResMed Meets Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.
The primar...
>>> Read more: ResMed Full Year 2024 Earnings: In Line With Expectations
